Neurotech International Limited announced further preliminary results of in-vitro human brain cell studies using its proprietary DOLCE/NTI cannabis leads. Neurotech has been undertaking a series of in-vitro studies to assess the neuro-protective, anti- inflammatory and neuro-modulatory activities of the proprietary DOLCE/NTI cannabis leads which include, CBDA, CBDP and CBDB conducted at three leading independent laboratories - Monash University, University of Wollongong and RMIT University. Further preliminary results demonstrate that the DOLCE/NTI full spectrum leads work through multiple neuronal mechanisms to provide potent neuro-modulatory and anti-inflammatory activity. The key conclusions of the study are summarised as follows: Studies have indicated that the DOLCE/NTI leads regulate multiple neuronal pathways which are directly involved in cell repair and rejuvenation. These leads indicate significant increased potency in repairing neuronal cells when compared to CBD alone (128.7% +/- 2.70 at 2ug/ml versus 81.2% +/- 4.255 at 10ug/ml respectively, n=5 95% CI, P<0.05). More importantly, concentrations five times lower of the DOLCE/NTI leads are needed to achieve these results when compared to CBD alone (2ug/ml versus 10ug/ml respectively). DOLCE/NTI leads work through a novel (different to CBD) mechanism. The DOLCE/NTI leads were shown to work through the powerful anti-inflammatory enzyme known as Arginase -1. Conversely, CBD alone did not produce any significant anti-inflammatory properties. DOLCE/NTI leads also increased the presence of beta-tubulin (n=3, 175.8 +/- 1.76 95% CI, P<0.05). Beta-tubulin is an essential protein in the maintenance and healthy survival of brain cells. In these studies, CBD alone did not produce an increase in beta-tubulin. Beta-tubulin is a vital protein in the management of a number of chronic neurological disorders such as Alzheimer's, Huntington's and Multiple Sclerosis. These studies provide further data to demonstrate the potential uniqueness of the DOLCE/NTI leads in their mode of action and their differentiation when compared to CBD alone. These findings allow Neurotech to fine tune the upcoming clinical program, select the optimum dose and patient parameters. Most importantly, the DOLCE/NTI leads contain very low levels of THC (<0.3%) which may result in a less onerous regulatory process and therefore a quicker path to commercialisation. Final results from the in-vitro trials are expected to be received next month.